Apex Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Apex Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$10.2M	Buy	250,037 +21,170	+9%	+$905K	0.22%	116
2015 Q4	$14.9M	Buy	228,867 +266	+0.1%	+$17.4K	0.33%	85
2015 Q3	$16.1M	Buy	228,601 +13,094	+6%	+$1.28M	0.37%	77
2015 Q2	$24M	Buy	215,507 +38,294	+22%	+$4.12M	0.51%	70
2015 Q1	$16.7M	Buy	+177,213	New	+$19.9M	0.39%	73

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FVF2

Flagship Ventures Fund 2007 Cambridge, Massachusetts $95.2M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Apex Capital Management's AGIO Position: Q1 2016 in Review

Apex Capital Management increased its Agios Pharmaceuticals (AGIO) stake by 9.2% in Q1 2016, buying an estimated $905K and bringing the position to 250,037 shares worth $10.2M. The position accounts for 0.22% of the portfolio, ranked #116.

Apex Capital Management first reported a position in AGIO in Q1 2015 and has held it in 5 quarters since. The position peaked at $24M in Q2 2015. 157 funds tracked by Wall St. Rank hold AGIO as of Q1 2016.

Apex Capital Management held 250,037 shares of Agios Pharmaceuticals worth $10.2M as of Q1 2016.
Apex Capital Management bought 21,170 Agios Pharmaceuticals shares in Q1 2016, an estimated $905K.
Agios Pharmaceuticals made up 0.22% of Apex Capital Management's portfolio in Q1 2016, its #116 holding.
Apex Capital Management first reported a position in Agios Pharmaceuticals in Q1 2015 and has held it in 5 quarters since.
Apex Capital Management's Agios Pharmaceuticals position peaked at $24M in Q2 2015.
157 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.